StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Friday morning. The firm issued a hold rating on the medical research company’s stock.

Several other equities analysts have also recently commented on the company. HC Wainwright reiterated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Cytosorbents has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

Cytosorbents stock opened at $1.30 on Friday. The stock has a market cap of $71.08 million, a P/E ratio of -3.61 and a beta of 0.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The stock has a 50 day moving average of $0.98 and a 200-day moving average of $1.04. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61.

Hedge Funds Weigh In On Cytosorbents

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Northern Trust Corp lifted its stake in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the last quarter. Skylands Capital LLC lifted its stake in Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Geode Capital Management LLC lifted its stake in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Cytosorbents during the fourth quarter worth $99,000. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.